home / stock / pptdf / pptdf short
Short Information | PeptiDream Inc (OTCMKTS:PPTDF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 24,516 |
Total Actual Volume | 26,256 |
Short Trends | |
---|---|
Cover Days | 1 |
Short Days | 19 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 1,226 |
Average Short Percentage | 95.58% |
Is there a PPTDF Short Squeeze or Breakout about to happen?
See the PPTDF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-03-2024 | $0 | $9.5 | $0 | $0 | 2 | 2 | 100% |
03-22-2024 | $9.5 | $9.5 | $9.5 | $9.5 | 205 | 205 | 100% |
10-27-2023 | $7.45 | $7.45 | $7.45 | $7.45 | 300 | 300 | 100% |
09-21-2023 | $0 | $11.6 | $0 | $0 | 1 | 1 | 100% |
09-14-2023 | $11.6 | $11.6 | $11.6 | $11.6 | 418 | 418 | 100% |
03-14-2023 | $13.4 | $13.4 | $13.4 | $13.4 | 100 | 100 | 100% |
02-17-2023 | $14.13 | $14.13 | $14.13 | $14.13 | 500 | 500 | 100% |
02-15-2023 | $14.1699 | $14.1699 | $14.1699 | $14.1699 | 100 | 100 | 100% |
01-30-2023 | $0 | $15.99 | $0 | $0 | 10 | 10 | 100% |
01-25-2023 | $15.99 | $15.99 | $15.99 | $15.99 | 340 | 300 | 88.24% |
12-29-2022 | $0 | $12.1 | $0 | $0 | 80 | 80 | 100% |
04-26-2022 | $15.97 | $15.97 | $15.97 | $15.97 | 100 | 100 | 100% |
04-25-2022 | $15.04 | $15.12 | $15.12 | $15.04 | 18,100 | 18,000 | 99.45% |
03-09-2022 | $15.335 | $15.335 | $15.335 | $15.335 | 500 | 500 | 100% |
02-24-2022 | $15.825 | $15.825 | $15.825 | $15.825 | 800 | 800 | 100% |
02-10-2022 | $17.98 | $18.06 | $18.06 | $17.98 | 1,000 | 1,000 | 100% |
02-08-2022 | $18.01 | $18.01 | $18.01 | $18.01 | 300 | 300 | 100% |
01-31-2022 | $18.17 | $18.17 | $18.17 | $18.17 | 1,000 | 1,000 | 100% |
01-26-2022 | $18.93 | $18.93 | $18.93 | $18.93 | 2,100 | 500 | 23.81% |
12-22-2021 | $24.96 | $24.96 | $24.96 | $24.96 | 300 | 300 | 100% |
News, Short Squeeze, Breakout and More Instantly...
PeptiDream Inc Company Name:
PPTDF Stock Symbol:
OTCMKTS Market:
NEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific mo...
NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific mol...
NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, today announced the presentation of proof-of-concept data on KPMW101, an anti-tum...